We should cautiously welcome this new therapeutic option On 5 March 2019 the US Food and Drug Administration approved esketamine nasal spray in conjunction with an oral antidepressant for people with treatment resistant depression. Esketamine is a form of ketamine. Definitions of treatment resistant ...
[3] Popova V, Daly E J, Trivedi M H, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Acti...
treatment resistant depression, OCD as well as psychopharmacology. He has been a Clinical Professor of Psychiatry at Cooper Medical School of Rowan University and an Associate Professor of Clinical Psychiatry at Temple University School of Medicine, Department of Psychiatry. He began his MPH training ...
背景:许多报道都暗示丁丙诺啡(buprenorphine)可能具有一定抗抑郁效果。在抑郁症患者中,有许多个体对于一线治疗方法均不响应,此类患者被归类为难治性抑郁症(treatment-resistant depression, TRD)。有关于抑郁症治疗的新方法需要更多地考虑对于这类患者的治疗。本项对于随机安慰剂对照试验的元分析研究,旨在评估丁丙诺啡作...
Esketamine has showcased promising results in a major clinical trial, proving more effective than standard treatments for treatment-resistant depression. Treatment-resistant depression (TRD) is a particularly challenging form of major depressive disorder. As Albino Oliveira-Maia, head of the Champalimaud ...
Intravenous (IV) esketamine is as safe and effective as IVketaminefor patients with treatment-resistantdepression, new research suggests. "Our study was the first randomized clinical trial directly comparing ketamine and esketamine in treatment-resistant depression," senior investigator Lucas C. Quarantini...
Johnson & Johnson submits a supplemental New Drug Application to the FDA for the approval of esketamine as a monotherapy for adults with treatment-resistant depression. Credit: US Food and Drug Admistration Johnson & Johnson announced on July 22, 2024 the submission of a supplemental New ...
[1] FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. Retrieved March 6, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-...
The US Food and Drug Administration has approved esketamine nasal spray (Spravato, Janssen Pharmaceuticals) for treatment-resistant depression.
[1] FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. Retrieved March 6, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-...